<!DOCTYPE html>
<html>
  <head>
      <meta charset="utf-8">
      <meta http-equiv="x-ua-compatible" content="ie=edge">
      <meta name="description" content="">
      <meta name="viewport" content="width=device-width, initial-scale=1">
      <script type='text/javascript'>if(console){console.error('Failed to load page metadata.')}</script>
      <title>Merck Is Finding PD-L1 Testing Is Helping Keytruda</title>
      <link rel="icon" type="image/png" href="/dist/img/favicon.png" />
      <link href='https://fonts.googleapis.com/css?family=PT+Serif:400,400italic|Roboto:400,300,500,700,400italic|Roboto+Condensed:400,700,700italic' rel='stylesheet' type='text/css'>
      <link rel="stylesheet" href="/dist/index-generated.css">
   </head>
   <body>
    <div class="pdf-header">
		<div class="pdf-logo" style="float:left;">
			<a href="/"><img src="../dist/img/logo.png" width="117px" height="54px"/></a>
		</div>
		<div style="float:right;">
			<div style="clear:both;">26 September 2016</div>
			<div style="clear:both;"><a href="#" style="color:red;">https://scrip.pharmamedtechbi.com</a></div>
		</div>
	</div>
	<hr/>
    <div class="pdf-body" style="clear:both;">
		<h1>Briefing title goes here </h1>
		<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque commodo justo nec sagittis ultricies.
		Aliquam aliquet dolor eu vestibulum fermentum. Fusce tincidunt elementum elit at ornare.</p>
		<div style="clear: both;">
			<ul>
				<li style="float: left; border-right:1px solid #d1d3d4; padding:0 10px 0 0;">26 Sept 2016</li>
				<li style="float: left; border-right:1px solid #d1d3d4; padding:0 10px 0 10px;"><strong>NEWS</strong></li>
				<li style="float: left; border-right:1px solid #d1d3d4; padding:0 10px 0 10px;"><font color="#F00">Regulation</font></li>
				<li style="float: left; border-right:1px solid #d1d3d4; padding:0 10px 0 10px;"><font color="#F00">Product Safety</font></li>
				<li style="float: left; padding:0 10px 0 10px"><font color="#F00">South Korea</font></li>
			</ul>
		</div>
		<div style="clear:both;"></div>
		<h1>PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing</h1>
		<p>by Brenda Sandburg</p>
		<div>
			<ul>
				<li style="color:#F00; padding:0 10px 0 0; border-right:1px solid #d1d3d4; float:left;">@brendasandburg</li>
				<li style="color:#F00;  padding:0 10px 0 10px; float:left;">Brenda.Sandburg@informa.com</li>
			</ul>
		</div>
		<div style="clear:both;"></div>
		<h3>Executive Summary</h3>
		<p>Spanish company PharmaMar has filed for approval of its anticancer Aplidin in the EU, which if successful would be its second product to reach the market.</p>
		<div style="clear:both;">
			<div style="float:left; width:790px;">
				<img src="../dist/img/SC1609_AplidiumAlbicans_1200x675.jpg"/>
				<div>
					<span style="text-transform:uppercase; float:left;">THIS IS AN IMAGE CAPTION</span>
					<span style="font-style:italic; float:right;">Source:PharmaMar</span>
				</div>
			</div>
			<div>
				<p>PharmaMar SA has filed for EU approval of its marine-derived anticancer agent Aplidin (plitidepsin) for use in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.</p>
				<p>The filing, which appears to be the product’s first, is based on data from the Phase III ADMYRE study, top- line data from which were releasedin March. This showed a significant 35% reduction in the risk of progression or death over dexamethasone alone, meeting its primary endpoint (p=0.0054). The trial enrolled more than 250 patients in the US, Europe and Asia Pacific who had relapsed or refractory disease following a minimum of three and no more than six prior therapeutic regimens.</p>
				<p>At the time, analysts from Informa Pharma’s Biomedtracker PharmaMar SA has filed for EU approval of its marine-derived anticancer agent Aplidin (plitidepsin) for use in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.</p>
				<p>The filing, which appears to be the product’s first, is based on data from the Phase III ADMYRE study, top-line data from which were released in March. This showed a significant 35% reduction in the risk of progression or death over dexamethasone alone, meeting its primary endpoint (p=0.0054). The trial enrolled more than 250 patients in the US, Europe and Asia Pacific who had relapsed or refractory disease</p>
			</div>
		</div>
	</div>
	<div style="clear: both;"></div>
	<hr/>
    <div class="pdf-footer">
		<div>© Copyright: Agribusiness Intelligence | Generated by [User] | 26 Sep 2016</div>
		<div>Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors</div>
		<hr/>
	</div>
	</body>
</html>	
